HILA approves access to Translarna™ the first treatment approved for the underlying cause of childhood muscle wasting disease

- Decision by the Finnish Pharmaceuticals Pricing Board (HILA) means access for ambulatory patients with nonsense mutation Duchenne muscular dystrophy from two years of age and older - Gothenburg, Sweden [October 18, 2021]– PTC Therapeutics announced the decision of the Finnish Pharmaceuticals Pricing Board [Lääkkeiden hintalautakunta] to allow access to Translarna™ (ataluren) when prescribed for the treatment of nonsense mutation DMD patients (nmDMD) to ambulatory patients aged two years and older.[1] The decision will take effect from 1[st] December 2021. “This is a momentous